Version 1
: Received: 2 March 2024 / Approved: 4 March 2024 / Online: 4 March 2024 (14:09:37 CET)
How to cite:
Varrassi, G.; Paladini, A.; Corno, C.; Coaccioli, S.; Finco, G.; Tiso, D.; Fornasari, D. A Decades-Long Journey of Palmitoylethanolamide (PEA), as a Cornerstone in Chronic Neuropathic Pain Management: A Comprehensive Narrative Review. Preprints2024, 2024030174. https://doi.org/10.20944/preprints202403.0174.v1
Varrassi, G.; Paladini, A.; Corno, C.; Coaccioli, S.; Finco, G.; Tiso, D.; Fornasari, D. A Decades-Long Journey of Palmitoylethanolamide (PEA), as a Cornerstone in Chronic Neuropathic Pain Management: A Comprehensive Narrative Review. Preprints 2024, 2024030174. https://doi.org/10.20944/preprints202403.0174.v1
Varrassi, G.; Paladini, A.; Corno, C.; Coaccioli, S.; Finco, G.; Tiso, D.; Fornasari, D. A Decades-Long Journey of Palmitoylethanolamide (PEA), as a Cornerstone in Chronic Neuropathic Pain Management: A Comprehensive Narrative Review. Preprints2024, 2024030174. https://doi.org/10.20944/preprints202403.0174.v1
APA Style
Varrassi, G., Paladini, A., Corno, C., Coaccioli, S., Finco, G., Tiso, D., & Fornasari, D. (2024). A Decades-Long Journey of Palmitoylethanolamide (PEA), as a Cornerstone in Chronic Neuropathic Pain Management: A Comprehensive Narrative Review. Preprints. https://doi.org/10.20944/preprints202403.0174.v1
Chicago/Turabian Style
Varrassi, G., Domenico Tiso and Diego Fornasari. 2024 "A Decades-Long Journey of Palmitoylethanolamide (PEA), as a Cornerstone in Chronic Neuropathic Pain Management: A Comprehensive Narrative Review" Preprints. https://doi.org/10.20944/preprints202403.0174.v1
Abstract
Palmitoylethanolamide (PEA) has been prescribed for neuropathic pain for several years. This study is mainly addressed to summarize what has been published on the topic in the last decades, and how appropriate the numerous prescriptions are. Among others, it examines the innovative EquiPEA® patent, which aims to address obstacles encountered with conventional PEA formulations. EquiPEA® seems to partially ameliorate the bioavailability and the targeted distribution. It seems to introduce novel advancements that have the potential to enhance the therapeutic effectiveness of PEA in terms of its anti-inflammatory, antioxidant, and analgesic properties. The deep literature analysis aims to examine the potential advantages of this innovative formulation, in the context of several pathological conditions that may benefit from this molecule. In particular, it investigates the potential enhanced bioavailability and targeted delivery system of EquiPEA®. Also, it tries to understand if it can modernize the field of therapy based on PEA, thus offering a better treatment option for individuals with long-term inflammation, oxidative stress, and neuropathic or mixed pain with a neuropathic component. The study examines the possible impact of EquiPEA® on personalized medicine strategies and its potential for translation into clinical practice. It analyses the possibilities that EquiPEA® has in enhancing patient outcomes in a range of central nervous system and inflammatory conditions. This narrative review makes a valuable contribution to the ongoing comprehension of PEA therapy. It establishes a foundation for further exploration in research and potential uses in clinical settings.
Medicine and Pharmacology, Anesthesiology and Pain Medicine
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
*
,
,
,
